LA NEURODEGENERAZIONE E LA NEUROPLASTICITÀ NEI DIVERSI FENOTIPI DELLA SCLEROSI MULTIPLA Diego Centonze.

Slides:



Advertisements
Similar presentations
Parkinson’s disease (PD) is one of the most common chronic progressive neurodegenerative diseases. PD has a prevalence of 1.2 million people in Europe.
Advertisements

Effect of Liraglutide Treatment on Inflammation and Oxidative Stress in Young and Old APP/PS1 and WT Mice Supervisors: Dr. Christian Holscher Dr. Kerry.
Synaptic Homeostasis Sean Sweeney Module 725. mEPSPs are recordings of release of one vesicle/quantum. EPSP is a suprathreshold stimulation Of the nerve.
What Factors Contribute to the Risk for MS?. Compston A, et al. McAlpine’s Multiple Sclerosis, 4 th ed. Churchill Livingston; Hauser SL, et al.
The three main phases of neural development 1. Genesis of neurons (and migration). 2. Outgrowth of axons and dendrites, and synaptogenesis. 3. Refinement.
Original Article B-Cell Depletion with Rituximab in Relapsing- Remitting Multiple Sclerosis Stephen L. Hauser, M.D., Emmanuelle Waubant, M.D., Ph.D., Douglas.
FREEDOMS II TRIAL.
Fingolimod Therapy for Multiple Sclerosis
AMPAKINE Compounds for the Treatment of Rett Syndrome
Non invasive oscillatory stimulation treatment for combating late-life accelerated cognitive decline Preservation of cortical network synchronicity and.
Epilepsy Lecture Neuro Course 4th year. Objectives – To Review: What the term epilepsy means Basic mechanisms of epilepsy How seizures and epilepsies.
Multiple Sclerosis Alan Chen 4/1/14. General Information Other names: disseminated sclerosis or encephalomyelitis disseminata Inflammatory disease that.
Neuroprotective Effects of Memantine. Hippocampal slice cultures Brown et al., Soc. Neurosci 2003 Semi-chronic 3-NP toxicity in organotypic hippocampal.
Sagittal FLAIR images - Stable nonenhancing hyperintensities within the pericallosal white matter and bilateral centrum semiovale, consistent with known.
A Randomized Placebo-Controlled Phase III Trial of Oral Laquinimod for Multiple Sclerosis Timothy L. Vollmer, MD Professor, Neurology and Neuroscience.
Wang haitao. Background Tinnitus, the perception of sounds in the absence of acoustic stimuli, often occurs as the result of hearing loss Tinnitus persists.
MRI as a Potential Surrogate Marker in the ADCS MCI Trial
Peptides from Scorpion Venom and Autoimmune diseases K. George Chandy, Department of Physiology and Biophysics, University of California Irvine.
The Inflammatory Nature of Cancer Pain Pawandeep Brar Palliative Care Physician Temmy Latner Centre for Palliative Care Mount Sinai Hospital.
Slide 1 Neuroscience: Exploring the Brain, 3rd Ed, Bear, Connors, and Paradiso Copyright © 2007 Lippincott Williams & Wilkins Bear: Neuroscience: Exploring.
Dennis Bourdette, MD VA MS Center of Excellence-West and
Neural Mechanisms of Learning & Memory Lesson 24.
APPROACHES TO THE BIOLOGY OF MEMORY Scale of analysis: –Micro: intra, intercellular –Medio: cell assemblies and neural networks –Macro: Coordinated brain.
Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.
Neuroprotective Effects of Memantine. Hippocampal slice cultures Brown et al., Soc. Neurosci 2003 Semi-chronic 3-NP toxicity in organotypic hippocampal.
ENDOCANNABINOID REGULATION OF ALTERNATIVE MICROGLIA ACTIVATION IN MULTIPLE SCLEROSIS CAITLIN JAGLA.
BY Mahsa Asadbeik In the Name of God. Introduction Signaling, Cellular Sources, and Biological Activities IL-17 cytokines and receptors family IL-17 in.
Alzheimer Disease (Senile Dementia) Characterized by progressive memory loss, is increasingly common in developed countries as populations include more.
Can the degree of meningeal inflammation and cortical pathology be used to stratify early progressive MS patients? R. Magliozzi, M. Calabrese, C. Cruciani,
Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease  C Bjartmar, J.R Wujek, B.D Trapp  Journal of.
Dynamic Neuroimmune Interactions in the Transition from Brain Function to Dysfunction NIH Blueprint Initiative, FY2018 Changhai Cui, Ph.D. NIAAA, NIH.
Camara M1, Anscomb H.L. 2 and Baune B.T. 1,2
International Neurourology Journal 2016;20:26-32
Gaman Elena Laura1, Stoian Irina1,2, Cirneci Dragos3
Astroglia and Learning
Ying Cheng (1st-year PhD), supervised by Dr Gayle Doherty
A potential therapy for ALS
Carl W. Cotman, Nicole C. Berchtold  Trends in Neurosciences 
CD46: role in multiple sclerosis
What Predicts Disability Progression in Multiple Sclerosis?
What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?
Can Primary Care Physicians Take the Lead in Combating Obesity?
Neuroinflammation and the generation of neuropathic pain
Nat. Rev. Neurol. doi: /nrneurol
Implications for Brain-Immunometabolism
Multiple Sclerosis. The role of microglia in regulating axon initial segment integrity in health and disease.
Stephen L. Hauser, Jorge R. Oksenberg  Neuron 
How Attenuation Of Microglial Cell Using Cre-Lox Can Effect Pathology of EAE Induce Mice By Kevin Limlengco.
Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.
Figure 1 Clinical correlates of neurodegeneration in MS
Figure 1 Evolution of multiple sclerosis
Nat. Rev. Neurol. doi: /nrneurol
Lithium: Mechanism of Action
Figure 3 VEGF in neurodegenerative disease
Figure 3 Biologics that attenuate effector responses in the kidney
Figure 4 Comparison of 7.0T and 3.0T MRI (patients 5 and 6)‏
S1P effect on cIAP2 knockout mice microglia during EAE, an animal model of multiple sclerosis Srikethan Mahavadi.
Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)
Figure 2 GM-CSF — a key player in inflammation and autoimmunity
Nat. Rev. Urol. doi: /nrurol
Myeloid Cells in the Central Nervous System
Microglia: New Roles for the Synaptic Stripper
Figure 7 VEGF as a mediator of neuroinflammatory disease
Multiple Sclerosis is a neurological, immune-mediated disorder
Figure 4 Shared and unique immune changes induced by multiple sclerosis (MS) immunomodulatory treatments Shared and unique immune changes induced by multiple.
Anh Pham Conserved epigenomic signals in mice and humans reveal immune basis of Alzheimer’s disease.
Figure 4 Alemtuzumab-mediated effects on interleukin (IL)–23 and granulocyte-macrophage colony-stimulating factor (GM-CSF) production in innate myeloid.
Figure 2 Natalizumab increases expression of proinflammatory genes and cytokines by CD49d+ memory CD4 cells Natalizumab increases expression of proinflammatory.
Figure 2 Effect of DMF therapy on the T helper cell repertoire and cytokine production Effect of DMF therapy on the T helper cell repertoire and cytokine.
Wolbachia-induced responses of specific cell types.
Presentation transcript:

LA NEURODEGENERAZIONE E LA NEUROPLASTICITÀ NEI DIVERSI FENOTIPI DELLA SCLEROSI MULTIPLA Diego Centonze

GRAY MATTER DEGENERATION IN MULTIPLE SCLEROSIS: A MATTER OF DENDRITES AND SYNAPSES? What’s lost in the atrophic cortex and deep nuclei of MS brain? Glia (astroglia, microglia)? Neurons (somata, axons, dendrites)? Kettenmann H et al., 2013 Neuron

Centonze D et al., 2009 J Neurosci CHRONIC INFLAMMATION CAUSES SYNAPTIC DAMAGE AND DENDRITIC LOSS IN THE GRAY MATTER OF EAE MICE

THE INFLAMMATORY MILIEU DIFFERS IN RELAPSING AND PROGRESSIVE MS PATIENTS Rossi S et al., 2011, Ann Neurol Rossi S et al., 2014, Mult Scler

A PREFERENTIAL ROLE FOR TNF IN THE NEURODEGENERATIVE PROCESS OF PMS? A PREFERENTIAL ROLE FOR IL-1  IN THE NEURODEGENERATIVE PROCESS OF RMS?

A PREFERENTIAL ROLE FOR TNF IN THE NEURODEGENERATIVE PROCESS OF PMS? A PREFERENTIAL ROLE FOR IL-1  IN THE NEURODEGENERATIVE PROCESS OF RMS?

“Recent evidence implicates molecules classically associated with the peripheral immune system in the modulation of homeostatic synaptic plasticity. In particular, the pro- inflammatory cytokine TNF , class I major histocompatibility complex, and neuronal pentraxin 2 are essential in the regulation of the compensatory synaptic response that occurs in response to prolonged neuronal inactivity.”

Wang G et al., Neural Plasticity 2012 TNF  ACTIVITY AND THE DOWNREGULATION OF ARC ARE KEY STEPS IN SYNAPTIC UP-SCALING

SYNAPTIC UP-SCALING IS MASSIVELY INDUCED IN A MOUSE MODEL OF PROGRESSIVE MS Centonze D et al., J Neurosci 2009 Haji N et al., Exp Neurol 2012

EVIDENCE OF SYNAPTIC UP-SCALING AND TNF-MEDIATED NEURODEGENERATION IN PROGRESSIVE MULTIPLE SCLEROSIS Rossi S et al., 2014 Mult Scler

EVIDENCE OF SYNAPTIC UP-SCALING AND TNF-MEDIATED NEURODEGENERATION IN PROGRESSIVE MULTIPLE SCLEROSIS Rossi S et al., 2014 Mult Scler

EVIDENCE OF SYNAPTIC UP-SCALING AND TNF-MEDIATED NEURODEGENERATION IN PROGRESSIVE MULTIPLE SCLEROSIS Studer V et al., 2014 J Neuroimmunol

A PREFERENTIAL ROLE FOR TNF IN THE NEURODEGENERATIVE PROCESS OF PMS? A PREFERENTIAL ROLE FOR IL-1  IN THE NEURODEGENERATIVE PROCESS OF RMS?

CSF FROM ACTIVE RMS PATIENTS ENHANCES THE FREQUENCY OF GLUTAMATERGIC SYNAPTIC CURRENTS IN BRAIN SLICES Stimulating electrode Recording electrode Rossi S et al., 2011, Ann Neurol

CSF FROM ACTIVE RMS PATIENTS CAUSES NEURONAL SWELLING Rossi S et al., 2011, Ann Neurol

IL-1  IS RESPONSIBLE FOR SYNAPTIC ALTERATIONS INDUCED BY CSF OF ACTIVE RMS PATIENTS Rossi S et al., 2011, Ann Neurol

IL-1  /IL-1ra RATIO CORRELATES WITH INTRACORTICAL FACILITATION EXPLORED BY MEANS OF pp-TMS IN RMS PATIENTS Rossi S et al., 2011, Ann Neurol

TO SUMMARIZE… Musella A et al., 2015 Mult Scler

SUMMARY & CONCLUSIONS The neurodegenerative process typical of MS seems to be mediated, at least in part, by excitotoxic mechanisms causing severe dendritic and synaptic loss in the gray matter. Pro-inflammatory cytokines, such as TNF (in PMS) and IL-1  (in RMS)  mediate the abnormalities of excitatory synaptic transmission through post- (TNF) and pre-synaptic (IL-1  effects  Understanding the specific mechanisms of inflammatory neurodegeneration in PMS and in RMS is crucial to develop treatments able to halt disease worsening and progression.

FREEDOMS: reduction in the rate of brain atrophy versus placebo over time Chin P et al. Poster P350 presented at ENS 2012 Change in mean BV from baseline (%) Placebo (n = 329) Fingolimod 0.5 mg (n = 356) –1.4 –1.2 –1.0 –0.8 –0.6 – –0.2 −35% vs placebo p= p< p= ITT population without multiplicity adjustments; p-values are for comparisons over Months 0-6, 0-12 and 0-24

FINGOLIMOD NORMALIZES ABNORMAL GLUTAMATERGIC TRANSMISSION IN EAE Rossi S et al., 2012 Br J Pharmacol

FINGOLIMOD IS NEUROPROTECTIVE IN EAE BY PREVENTING GLUTAMATE-MEDIATED SYNAPTOPATHY Rossi S et al., 2012 Br J Pharmacol